Mainz Biomed (MYNZ) Stock Analysis: AI Score & Alternative Data
Alt-data signals are cooling for Mainz Biomed
Is Mainz Biomed a buy right now? The alternative data says hold. This MYNZ stock analysis is built on the 25+ alternative data signals AltIndex tracks on Mainz Biomed every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 46/100: a Hold. The stock trades at $0.84 with a $8M market cap.
The soft spots over the past 90 days: web traffic down 95.6% to 147 monthly visits. The rest of the signal set is holding steady, which keeps MYNZ at a hold rather than a sell.
MYNZ’s broader alt-data profile also covers headcount (26 employees, according to LinkedIn), X followers (8K), and sentiment (93/100). Every signal links to its own page with full history, the MYNZ technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on MYNZ is just below.
Mainz Biomed AI Stock Analysis
Mainz Biomed is a biotechnology company primarily focused on the development of diagnostic solutions for life-threatening conditions. The company has garnered attention for its innovative research and development in the medical diagnostic field.
Analysis generated October 3, 2026.
Recent Mainz Biomed Stock Alerts
|
Mainz Biomed | May 6 Twitter followers are up by 2.2% in the last 24h. |
|
Mainz Biomed | April 23 Twitter followers are up by 13.9% in the last 24h. |
|
Mainz Biomed | April 2 Twitter followers are up by 3.5% in the last 24h. |
|
Mainz Biomed | March 11 Price is down by -6.9% in the last 24h. |
Mainz Biomed Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 147 | 95.6% | |
| Job Posts | 0 | N/A | |
| LinkedIn Employees | 26 | 0% | |
| Sentiment | 93 | 0% | |
| Reddit Mentions | 0 | N/A | |
| X Mentions | 1 | 95.2% | |
| Stocktwits Mentions | 40 | 0% | |
| News Mentions | 0 | N/A | |
| Stocktwits Subscribers | 17K | 0% | |
| 4chan Mentions | 0 | N/A | |
| X Followers | 8K | 1.7% | |
| Facebook Followers | 612 | 0.8% | |
| Facebook Engagement | 0 | N/A |
About Mainz Biomed (MYNZ)
Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe.
| Price | $0.84 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $8M |
| Year Range | $1 – $3 |
| Dividend Yield | 0% |
| PE Ratio | — |
| Analyst Rating | 38% buy |
| Industry | Biotechnology |
Latest Mainz Biomed News
View more →
Mainz Biomed Announces Appointment of Robert Liscouski as Chairman of the Board of DirectorsMarch 11 - GlobeNewswire |
|
Mainz Biomed To Present Poster Titled BLOOD-BASED MRNA SIGNATURE FOR DETECTION OF PANCREATIC DUCTAL ADENOCARCINOMA AND DISCRIMINATION OF INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS At Digestive Disease Week In ChicagoFebruary 23 - Benzinga |
|
Mainz Biomed shares are trading lower. The company announced a $6 million private placement and strategic updates.February 16 - Benzinga |
|
 |
Mainz Biomed Announces 6.0 USD Million Private Placement and Strategic UpdateFebruary 16 - Yahoo |
Mainz Biomed Raises $6M Private Placement To Fund Operations And Shift Focus To Pancreatic Cancer ScreeningFebruary 16 - Benzinga |
|
See Mainz Biomed’s complete price and AI Score history
Sign up to unlock 1-year and all-time charts for MYNZ, plus 25+ alternative data signals, AI Scores, and real-time alerts.
Get Started for FREEMainz Biomed Earnings & Financial Performance
View all earnings →Mainz Biomed Insider Trading Activity
View all →| Donahue Kevin Michael filed to sell 643,850 shares at $0.0. Oct 17 '25 |
| Donahue Kevin Michael filed to sell 685,000 shares at $0.0. Oct 17 '25 |
Mainz Biomed Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| No congress trades on file. | |||
Stocks Similar to Mainz Biomed
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
OSR HoldingsOSRH |
$0.22 2.3% | $8M | 53 |
 |
NKGen BiotechNKGN |
$0.01 0.0% | $8M | 46 |
 |
SoligenixSNGX |
$0.35 1.3% | $8M | 41 |
 |
NeuroSense TherapeuticsNRSN |
$3.82 6.1% | $8M | 48 |
 |
Brainstorm CellBCLI |
$0.90 12.6% | $8M | 44 |
Explore Mainz Biomed Data
Frequently Asked Questions: Mainz Biomed (MYNZ)
Mainz Biomed has an AltIndex AI Score of 46/100 (Hold). The score reflects mixed alternative data signals. All investments carry risk.
46/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of Mainz Biomed (MYNZ) stock is $0.84 with a market cap of $8M.
As of today, Mainz Biomed’s PE (Price to Earnings) ratio is —.
View the latest Mainz Biomed insider transactions to see recent buying and selling activity by company executives and directors.
Check the Mainz Biomed congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The MYNZ stock price chart above shows Mainz Biomed’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full Mainz Biomed technical analysis for RSI, moving averages, and more.
See the stocks similar to Mainz Biomed section on this page for companies in the same industry ranked by market cap and AI Score.
